接口广告
摩熵化学
数据开放平台 数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[2-(1,3-benzodioxol-5-yl)ethyl]propan-2-amine

中文名称
——
中文别名
——
英文名称
N-[2-(1,3-benzodioxol-5-yl)ethyl]propan-2-amine
英文别名
——
N-[2-(1,3-benzodioxol-5-yl)ethyl]propan-2-amine化学式
CAS
——
化学式
C12H17NO2
mdl
MFCD01135976
分子量
207.27
InChiKey
RUFYXZYDGVTZFQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    30.5
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • [EN] SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF<br/>[FR] MODULATEURS À PETITES MOLÉCULES DE RÉCEPTEURS SIGMA-1 ET SIGMA-2 ET LEURS UTILISATIONS
    申请人:UNIV NORTHWESTERN
    公开号:WO2020112846A1
    公开(公告)日:2020-06-04
    This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a tetrahydroindazole structure which function as modulators (e.g., activators or inhibitors) of sigma-1 and/or sigma-2 receptors, and their use as therapeutics for the treatment of cancer and other diseases (e.g., neurological conditions) characterized with sigma-1 and/or sigma-2 receptor activity.
    这项发明属于药物化学领域。具体来说,该发明涉及一类具有四氢吲哚结构的小分子,其作为sigma-1和/或sigma-2受体的调节剂(例如,激活剂或抑制剂),以及它们作为治疗癌症和其他疾病(例如,具有sigma-1和/或sigma-2受体活性的神经系统疾病)的药物的用途。
  • THYROID RECEPTOR LIGANDS
    申请人:Ryono Denis E.
    公开号:US20100298276A1
    公开(公告)日:2010-11-25
    Thyroid receptor ligands are provided which have the general formula I wherein: R 1 is R 2 and R 3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, provided that at least one of R 2 and R 3 is other than hydrogen; R 4 is R 5 and R 6 are the same or different and are selected from hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, aralkyl or heteroaralkyl. R 7 is aryl, heteroaryl, alkyl, aralkyl, or heteroaralkyl; R 8 is aryl, heteroaryl, or cycloalkyl; R 9 is R 7 or hydrogen; R 10 is hydrogen, halogen, cyano or alkyl; R 11 and R 12 are each independently selected from the group consisting of hydrogen, halogen, alkoxy, hydroxy (—OH) cyano, and alkyl; R 13 is carboxylic acid (COOH) or esters thereof, phosphonic and phosphinic acid or esters thereof, sulfonic acid, tetrazole, hydroxamic acid, thiazolidinedione, acylsulfonamide, or other carboxylic acid surrogates known in the art; R 14 and R 15 may be the same or different and are selected from hydrogen and alkyl, or R 14 and R 15 may be joined together forming a chain of 2 to 5 methylene groups [—(CH2)m-, m=2, 3, 4 or 5], thus forming 3- to 6-membered cycloalkyl rings; R 16 is hydrogen or alkyl of 1 to 4 carbons; R 17 and R 18 are the same or different and selected from hydrogen, halogen and alkyl; n is 0 or an integer from 1 to 4; X is oxygen (—O—), sulfur (—S—), sulfonyl (—SO 2 —), sulfenyl (—SO—) selenium (—Se—), carbonyl (—CO—), amino (—NH—) or methylene (—CH2-); wherein the substituents are as described herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T 3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.
    提供了甲状腺受体配体,其具有一般公式I,其中:R1为R2和R3,R2和R3相同或不同,为氢、卤素、1至4个碳原子的烷基或3至5个碳原子的环烷基,但至少其中一个为非氢;R4为R5和R6,R5和R6相同或不同,选择自氢、芳基、杂环芳基、烷基、环烷基、芳基烷基或杂环芳基;R7为芳基、杂环芳基、烷基、芳基烷基或杂环芳基;R8为芳基、杂环芳基或环烷基;R9为R7或氢;R10为氢、卤素、基或烷基;R11和R12各自独立选择自氢、卤素、烷氧基、羟基(—OH)、基和烷基;R13为羧酸(COOH)或其酯、膦酸膦酸酯、磺酸四唑羟胺酸、噻唑二酮、酰基磺胺或艺术中已知的其他羧酸替代物;R14和R15可相同或不同,选择自氢和烷基,或R14和R15可结合形成2至5个亚甲基组成的链[—(CH2)m-,m=2、3、4或5],从而形成3至6成员的环烷基环;R16为氢或1至4个碳原子的烷基;R17和R18相同或不同,选择自氢、卤素和烷基;n为0或1至4的整数;X为氧(—O—)、(—S—)、砜基(—SO2—)、砜基(—SO—)、(—Se—)、羰基(—CO—)、基(—NH—)或亚甲基(— -);其中取代基如上述所述。此外,提供了一种方法,用于预防、抑制或治疗与代谢功能障碍或依赖于T3调节基因表达的疾病或障碍,其中上述化合物以治疗有效剂量给予。
  • Photoreactive ligands and uses thereof
    申请人:The Scripps Research Institute
    公开号:US11535597B2
    公开(公告)日:2022-12-27
    Disclosed herein are methods for identifying proteins as targets for interaction with a small molecule ligand. Also disclosed herein are small molecule ligands and compositions for use in profiling druggable proteins.
    本文公开了用于确定蛋白质作为与小分子配体相互作用的靶标的方法。本文还公开了用于分析可药用蛋白质的小分子配体和组合物。
  • PHOTOREACTIVE LIGANDS AND USES THEREOF
    申请人:The Scripps Research Institute
    公开号:US20200071277A1
    公开(公告)日:2020-03-05
    Disclosed herein are methods for identifying proteins as targets for interaction with a small molecule ligand. Also disclosed herein are small molecule ligands and compositions for use in profiling druggable proteins.
  • US7557143B2
    申请人:——
    公开号:US7557143B2
    公开(公告)日:2009-07-07
查看更多

同类化合物

(5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) 黄樟素氧化物 黄樟素乙二醇; 2',3'-二氢-2',3'-二羟基黄樟素 黄樟素 风藤酰胺 风藤酮 非哌西特盐酸盐 非哌西特 盐酸盐 角秋水仙碱 螺[1,3-苯并二氧戊环-2,1'-环己烷]-5-胺 蓝细菌 苯并[d][1,3]二氧杂环戊烯-5-胺盐酸盐 苯并[d][1,3]二氧代l-5-甲基(2-氧代乙基)氨基甲酸叔丁酯 苯并[d][1,3]二氧代l-5-氨基甲酸叔丁酯 苯并[d][1,3]二氧代-4-甲腈 苯并[d][1,3]二氧代-4-氨基甲酸叔丁酯 苯并[d[1,3]二氧代-4-羧酰胺 苯并[1,3]二氧杂环戊烯-5-基甲基2-氯乙酸酯 苯并[1,3]二氧杂环戊烯-5-基甲基-苄基-胺 苯并[1,3]二氧杂环戊烯-5-基甲基-[2-(4-氟-苯基)-乙基]-胺 苯并[1,3]二氧杂环戊烯-5-基甲基-(四氢-呋喃-2-基甲基)-胺 苯并[1,3]二氧杂环戊烯-5-基甲基-(2-氟-苄基)-胺 苯并[1,3]二氧杂环戊烯-5-基甲基-(1-甲基-哌啶-4-基)-胺 苯并[1,3]二氧代l-5-甲基-吡啶-3-甲基-胺 苯并[1,3]二氧代l-5-甲基-(4-氟-苄基)-胺 苯并[1,3]二氧代l-5-乙酸甲酯 苯并[1,3]二氧代-5-羧酰胺盐酸盐 苯并[1,3]二氧代-5-甲基肼盐酸盐 苯并[1,3]二氧代-5-甲基吡啶-4-甲胺 苯并[1,3]二氧代-5-甲基-吡啶-2-甲胺 苯并[1,3]二氧代-5-乙酰氯 苯并-1,3-二氧杂环戊烯-5-甲醇丙酸酯 苯乙酸,1-(1,3-苯并二氧杂环戊烯-5-基)-3-丁烯-1-基酯 苯乙酮O-((4-(3,4-亚甲二氧基苄基)-1-哌嗪-1-基)羰基甲基)肟 苯,1-甲氧基-6-硝基-3,4-亚甲二氧基- 芝麻酚 芝麻林素 脲,N-1,3-苯并二噁唑-5-基-N'-(2-溴乙基)- 胡椒醛肟 胡椒醛-((Z)-O-苯基氨基甲酰基肟) 胡椒醛,二苄基缩硫醛 胡椒醛 胡椒醇 胡椒酸酰氯 胡椒酸 胡椒腈 胡椒环乙酮肟 胡椒环 胡椒基重氮酮 胡椒基甲醛